The Changing Landscape of Treatment for Cystic Fibrosis Related Diabetes

被引:1
|
作者
Amini, Mehdia [1 ]
Yu, Kevin [1 ]
Liebich, Jessica [1 ]
Ahir, Vaishaliben [1 ]
Wood, Emily [1 ]
Albert, Stewart [1 ]
Dhindsa, Sandeep [1 ]
机构
[1] St Louis Univ, Div Endocrinol Diabet & Metab, Sch Med, St Louis, MO 63110 USA
关键词
Cystic fibrosis; Diabetes; Elexacaftor; Tezacaftor; Ivacaftor; ASSOCIATION;
D O I
10.1016/j.jcte.2024.100332
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Patients with Cystic Fibrosis related diabetes [CFRD] are treated with insulin and high calorie diets to maintain body mass. The combined CFTR modulator elexacaftor/tezacaftor/ivacaftor [ETI] decreases pulmonary exacerbations and improves nutritional status. We reviewed the effects of ETI on BMI, HbA1c and diabetes regimen in patients with CFRD over a period of three years.<br /> Methods: Data of previously CFTR-modulator-na & iuml;ve patients with CFRD and pancreatic insufficiency on ETI therapy were retrieved from an electronic health record database. Patients were followed for a mean duration of 2.7 +/- 0.8 years after ETI initiation. Data pertaining to weight, BMI, HbA1c and diabetes regimen were collected at 6 months, 12 months, 2 years and at 3 years post-ETI initiation. Patients were then dichotomized based on their baseline BMI into a low BMI group and an "at target" BMI group. The effects of ETI on changes in weight, BMI, A1c and diabetes regimen were compared in both groups over a period of three years.<br /> Results: Twenty-seven patients with CFRD (15 men/12 women), age 30.6 +/- 11.5 (SD) years, BMI 22.4 +/- 4.0 kg/ m(2), were included. Fifteen patients had low BMI (<22 kg/m(2) for women, <23 kg/m(2) for men) and 12 patients had at target BMI (>= 22 kg/m(2 )for women, >= BMI 23 kg/m(2) for men). Patients with low BMI had an increase in their BMI from 19.5 +/- 1.7 to 21.4 +/- 2.2 kg/m(2 )at one year (p = 0.002), and 21.8 +/- 1.8 kg/m(2) at three years (p = 0.004) after ETI initiation. Four patients (out of 15) in the low BMI group had achieved normal BMI by the end of study follow up. There was no change in weight in the at target BMI group. HbA1c and basal insulin requirements did not change in either group. Five patients started non-insulin therapies.<br /> Conclusion: BMI increased after ETI therapy in CFRD patients with low BMI, but not in those with at target BMI. The use of non-insulin therapies is increasing in CFRD and should be evaluated in future studies.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Cystic fibrosis: A changing landscape
    Wendekier, Camille
    Wendekier-Raybuck, Katheryn
    [J]. NURSE PRACTITIONER, 2021, 46 (09): : 48 - 55
  • [2] TREATMENT OF CYSTIC FIBROSIS-RELATED DIABETES
    Yoon, John
    [J]. PEDIATRIC PULMONOLOGY, 2018, 53 : 44 - 45
  • [3] Changing landscape of cystic fibrosis related diabetes (CFRD): Is there a role for DPP4 inhibitor therapy? Experience from a cystic fibrosis specialist centre
    Santhakumar, A.
    Winterbottom, H.
    Pickles, J.
    Punt, S.
    Toufeeq, K.
    Lewis, F.
    Beynon, J.
    Barry, P.
    Brennan, A.
    [J]. DIABETIC MEDICINE, 2023, 40
  • [4] Treatment of cystic fibrosis-related diabetes reply
    Ballmann, Manfred
    Holl, Reinhard W.
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (03): : 167 - 168
  • [5] Cystic fibrosis related diabetes
    Zirbes, Jacquelyn
    Milla, Carlos E.
    [J]. PAEDIATRIC RESPIRATORY REVIEWS, 2009, 10 (03) : 118 - 123
  • [6] Cystic Fibrosis Related Diabetes
    Donal O’Shea
    Jean O’Connell
    [J]. Current Diabetes Reports, 2014, 14
  • [7] Cystic Fibrosis Related Diabetes
    O'Shea, Donal
    O'Connell, Jean
    [J]. CURRENT DIABETES REPORTS, 2014, 14 (08)
  • [8] Cystic Fibrosis Related Diabetes
    Banjar, Hanaa
    AlBanyan, Sara
    [J]. HORMONE RESEARCH IN PAEDIATRICS, 2016, 86 : 248 - 249
  • [9] Challenges in the dietary treatment of cystic fibrosis related diabetes mellitus
    Wilson, DC
    Kalnins, D
    Stewart, C
    Hamilton, N
    Hanna, AK
    Durie, PR
    Tullis, E
    Pencharz, PB
    [J]. CLINICAL NUTRITION, 2000, 19 (02) : 87 - 93
  • [10] Cystic Fibrosis - Related Diabetes Mellitus
    Lorini, R
    Minicucci, L
    Giannattasio, A
    Cotellessa, M
    [J]. PROCEEDINGS OF 25TH EUROPEAN CYSTIC FIBROSIS CONFERENCE, 2002, : 213 - 218